Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Zunsemetinib (CDD-450) is a potent and specific inhibitor of the p38α-MK2 pathway, exerting its effects through oral administration. It has proven activity against immuno-inflammatory diseases, making it a valuable tool for research in this area.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Inquiry | $ 697.00 | |
10 mg | Inquiry | $ 1,190.00 |
Description | Zunsemetinib (CDD-450) is a potent and specific inhibitor of the p38α-MK2 pathway, exerting its effects through oral administration. It has proven activity against immuno-inflammatory diseases, making it a valuable tool for research in this area. |
In vitro | Zunsemetinib, at concentrations of 1 and 10 μM for 1 hour in WT and NOM ID BMMs, does not alter NLRP3 expression but effectively lowers IL-1β expression by facilitating the degradation of IL-1β mRNA. Similarly, when applied over 16 hours in PBMCs at doses ranging from 0.4 nM to 1 μM, it diminishes IL-1β secretion and induces IL-1β mRNA instability. The compound uniquely inhibits the p38α MAPK pathway's activation of MK2, a proinflammatory kinase, without affecting the activation of other pathways such as PRAK and ATF2. Additionally, Zunsemetinib prevents the formation of osteoclasts in vitro, a process triggered by RANKL. This demonstrates its role in not just modulating specific gene expressions but also its potential in affecting cellular inflammatory responses and osteoclastogenesis. |
In vivo | Zunsemetinib, administered orally at 1,000 ppm, effectively inhibits LPS-induced TNF-α expression for up to four weeks post-dosing, as demonstrated in 8-week-old WT female mice[1]. At dosages of 10 and 20 mg/kg, this compound also significantly enhances bone density in rats, indicating a potential therapeutic application in bone health[1]. Furthermore, Zunsemetinib prevents osteopenia in NOM ID c mice by inhibiting osteoclastogenesis, showcasing its multifaceted role in bone metabolism regulation[1]. |
Synonyms | CDD-450, ATI-450 |
Molecular Weight | 513.93 |
Formula | C25H22ClF2N5O3 |
CAS No. | 1640282-42-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Zunsemetinib 1640282-42-3 CDD 450 ATI450 CDD450 CDD-450 ATI-450 ATI 450 inhibitor inhibit